Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Abingdon Health PLC (AIM:ABDX) Completion of Technical Transfer & initial orders
Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNowTM test
Abingdon Health PLC (ABDX.L) Update on AffiDX® SARS-CoV-2 antigen LFT
Technical transfer completed mid-December as planned
The lateral flow tycoons. How a small UK company (property agency and shoe retailer), went from being indebted to £3,500 to a profit of £20M
Thanks to its role in the largest ever government Covid deal, a tiny British company saw its value rise from zero to over £20million per year.
Abingdon Health PLC (ABDX.L) Preliminary Results
York, U.K. 18 November 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces its preliminary results for the year
Abingdon Health PLC (ABDX.L) Launch of Semi-Quantitative Accessory to AbC-19T
To help indicate the strength of antibody response and possible immunity
Abingdon Health PLC (ABDX.L) Launch of BioSURE COVID-19 IgG Antibody Self Test
Contract manufacturing for CE marked self-test to monitor antibody status
Abingdon Health PLC (ABDX.L) Exclusive Manufacturing Agreement with BioSure
Exclusive Lateral Flow Manufacturing Agreement with BioSure UK Limited